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Background. Phase I of this study was aimed at comparing the profiles of oxidative stress biomarkers in patients with history of
nonmelanoma skin cancer (NMSC), previously treated with surgery, to the healthy subjects. Phase II aimed to evaluate the effects of
supplementary antioxidant therapy on the levels of biomarkers in the case group.Materials andMethods. In Phase I, oxidative stress
biomarkers were measured in blood samples obtained from 24 healthy subjects and 60 patients with history of NMSC previously
treated with surgery. In Phase II, the 60 patients with history of NMSCwere randomized into two subgroups, one receiving placebo
(𝑛 = 34) and the other (𝑛 = 26) receiving vitamin C, vitamin E, and zinc supplementation for 8 weeks, followed by reevaluation of
biomarkers. Results. In Phase I, patients with history of NMSC showed increased plasma concentrations of all biomarkers, but only
15-F
2t-isoprostane was significantly higher than in the healthy subjects. Risk of NMSC increased by 4% for each additional 1 pg/mL
increase in 15-F
2t-isoprostane. In Phase II, supplementation did not significantly reduce levels of oxidative stress biomarkers.
Conclusion. Patients with history of NMSC had significantly high 15-F
2t-isoprostane plasma levels; supplementation did not result
in significant reduction of oxidative stress biomarkers. This trial was registered with ClinicalTrials.gov (ID NCT02248584).
1. Introduction
Oxidative stress occurs when there is disequilibrium between
the generation of reactive oxygen and nitrogen species
(ROS-RNS) and the cellular antioxidant system and may
result in significant damage to cellular structures as well as
nucleotides, proteins, and lipids. Lipid peroxidation generates
a variety of relatively stable decomposition products, such as
isoprostanes [1], which can be measured in plasma and urine
as indirect biomarkers of cellular prooxidant status.
Substantial evidence suggests that oxidative stress is a
prominent feature ofmany acute and chronic diseases includ-
ing cancer, cardiovascular disease, and neurodegenerative
pathologies, as well as being part of the normal aging pro-
cess [2, 3]. Oxidant-mediated alterations may contribute to
numerous skin disorders ranging from photosensitivity to
cancer. This has led to the search for nontoxic antioxidants
that could potentially minimize and/or reverse these changes
[4].
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Skin cancer is one of the most important and common
cancers, with considerably more than a million new cases
diagnosed each year worldwide [5]. Skin cancer is commonly
grouped into two different categories, melanoma skin cancer
(MSC) and nonmelanoma skin cancer (NMSC), based on the
cell of origin and clinical behavior. The incidence of NMSC
is much higher than that of melanoma. Fortunately, the vast
majority of NMSCs are much easier to treat than MSCs and
have a considerably better long-term prognosis. There are
strong epidemiologic and molecular data linking all forms
of skin cancer to sunlight exposure, and it is estimated that
ultraviolet (UV) radiation is the primary cause of nearly 90%
of NMSCs [6]. A component of sunlight is UVA radiation,
which penetrates deeper into the skin than UVB due to its
longer wavelengths. While UVA can indirectly damage DNA
through the formation of ROS, such as the superoxide anion,
hydrogen peroxide, and the hydroxyl radical [7], UVB can
directly damage DNA leading to the apoptosis of sunburn
cells in skin [5]. ROS may induce extensive DNA damage,
lead to cross-links between DNA and proteins, and cause
DNA and chromosomal aberrations that may be mutagenic
[8]. ROS may also be involved in tumorigenesis through the
activation of procarcinogens to generate free radicals that can
attack nucleophiles [4].
The purpose of the present study was to compare the
profiles of oxidative stress biomarkers, especially 15-F2t-
isoprostane, of patients with a history of NMSC previously
treated by surgery (case group) with those of healthy subjects
(comparison group) (Phase I) and to determine whether
supplementation with antioxidants could influence the levels
of biomarkers in the case group (Phase II).
2. Materials and Methods
This was a two-phase study composed of Phase I, with a
cross-sectional study design, and Phase II, a double-blind,
randomized, placebo-controlled trial, carried out between
January 2011 and December 2011 in Teresina, Piauı´, Brazil.
The study was approved by the local ethics committee, and
all participants provided a signed informed consent form
authorizing use of their data.
2.1. Characterization of Groups, Recruitment, and Eligibility.
In Phase I, the case group (𝑛 = 64) consisted of patients with
a history of NMSC (squamous cell carcinoma or basal cell
carcinoma) treated with surgery, recruited from a hospital in
Teresina, Piauı´, while the comparison group (𝑛 = 24) was
composed of workers from a university in Teresina, Piauı´,
with no history of NMSC. In Phase II, the patients in the case
group were randomized into two subgroups, one receiving
placebo (𝑛 = 34) and the other receiving supplementary
antioxidant therapy (𝑛 = 26).
The inclusion criteria for all participants were as follows:
age ≥20 years; absence of comorbidities such as type 1
diabetes, severe heart disease, hepatic dysfunction, renal
failure requiring dialysis, HIV infection, or MSC; no his-
tory of chemotherapy or radiotherapy in the previous 6
months; absence of severe psychiatric disease that limited
Table 1: Dietary reference intakes (UL–DRIs) and recommenda-
tions of the Institute of Medicine/National Academy Press [9, 10].
Gender DRI
Vitamin A Male 625 𝜇g/d
Female 500 𝜇g/d
Vitamin C Male 75mg/d
Female 60mg/d
Vitamin E Male 12mg/d
Female 12mg/d
Cuprum Male 700 𝜇g/d
Female 700 𝜇g/d
Zinc Male 9.4mg/d
Female 6.8mg/d
Selenium Male 45 𝜇g/d
Female 45 𝜇g/d
comprehension; and no taking of any vitamin and/ormineral
supplementation. Subjects in the case group who did not
complete the entire course of supplemental therapy were
excluded from the study during Phase II.
2.2. Sociodemographic Characteristics. Sociodemographic
characteristics of both the comparison and case groups
were collected using a standardized form that included
age, gender, race, smoking and alcohol habits (yes or no),
actual use of sunscreen, sunlight exposure, and family
history of cancer. In the case group, information regarding
histopathological parameters and tumor localization was
also collected.
2.3. Anthropometric and Dietary Investigations. Anthropo-
metric characteristics were assessed for both groups, and
a food frequency questionnaire was used to estimate the
daily intake of vitamins and minerals for each patient.
Dietary reference intakes (DRIs) established by the Institute
of Medicine of the National Academies were used to evaluate
the necessity of supplemental therapy (Table 1).
2.4. Supplemental Antioxidant Therapy. The placebo group
and supplemented group received, respectively, a placebo
capsule containing only lactose and an identical capsule
containing vitamin C (500mg; CVS Quality, USA), vitamin
E (400 IU; CVS Quality), and zinc (50mg; Nature’s Bounty,
USA) per day for 60 days. The concentrations of antioxi-
dants administered were determined according to the DRI
Tolerable Upper Intake Level (UL) and recommendations
of the Institute of Medicine/National Academy Press [9, 10]
(Table 1).
2.5. Oxidative Stress Biomarkers. Oxidative stress biomark-
ers including 15-F2t-isoprostane, thiobarbituric acid reactive
substances (TBARS), nitrite, and total antioxidant capacity
(TAC)weremeasured in plasma.All analyseswere performed
for both the comparison and case groups. The comparison
group was evaluated only in Phase I. The case group was
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Table 2: Comparison regarding sociodemographic characteristics from comparison and case groups.
Comparison (𝑛 = 24) Case (𝑛 = 60) 𝑝 value
Sociodemographic characteristics
Age (years) (mean ± SD) 56.7 ± 11.6 62.7 ± 14.2 0.0492a
Sex (female), 𝑛 (%) 19 (79.2) 39 (65.0) 0.2045b
Smoking, 𝑛 (%) 3 (12.5) 8 (13.3) 0.6645c
Alcoholism, 𝑛 (%) 3 (12.5) 9 (15.0) 0.7307c
Use of sunscreen, 𝑛 (%) 6 (25.0) 41 (68.3) 0.0003b
Mean daily sunlight exposure (min) (mean ± SD) 35.0 ± 28.9 180.5 ± 123.7 <0.0001a
Family history of cancer, 𝑛 (%) 4 (16.7) 42 (70.0) <0.0001b
Race, 𝑛 (%) 0.1377b
Caucasian 8 (33.3) 11 (18.3)
Non-Caucasian 16 (66.7) 49 (81.7)
Anthropometric parameters (mean ± SD)
BMI (kg/m2) 27.3 ± 3.5 26.5 ± 3.7 0.2710a
TSF (mm) 20.2 ± 6.8 18.3 ± 7.8 0.1750a
MUAC (cm) 30.9 ± 3.1 30.1 ± 4.5 0.1910a
MAMC (cm) 24.6 ± 3.0 24.5 ± 4.0 0.7100a
Daily intake levels (mean ± SD)
Vitamin A (𝜇g) 380.9 ± 197.1 558.0 ± 570.0 0.0015a
Vitamin C (mg) 162.4 ± 419.3 57.9 ± 50.6 0.2223a
Vitamin E (mg) 6.1 ± 14.2 9.6 ± 7.0 0.0018a
Cuprum (𝜇g) 1040.0 ± 1009.0 800.0 ± 400.0 0.0331a
Zinc (𝜇g) 10.1 ± 12.6 6.5 ± 3.6 0.0317a
Selenium (𝜇g) 52.2 ± 44.5 76.2 ± 38.8 0.0285a
𝑁= total of subjects/patients, SD = standard deviation, BMI = bodymass index, TSF = triceps skinfold,MUAC=mid-upper-arm circumference, andMAMC=
mid-arm muscle circumference. Statistical analysis: aMann-Whitney test; bChi-square test; cFisher’s exact test.
evaluated at two different times: (a) one day before the
start of supplementation or placebo administration and (b)
one day after the finish of intervention period. A total of
10mL of venous blood was obtained from all subjects. Blood
was withdrawn into blood collection tubes with EDTA or
citrate as an anticoagulant and centrifuged (2500 rpm for
10min at 4∘C), and the plasma was stored at −80∘C until
analysis. Each test for oxidative stress biomarkers required
1mL plasma.The plasma concentration of 15-F2t-isoprostane
was determined by enzyme-linked immunosorbent assay
(Isoprostane Express EIAKit; Cayman,USA). PlasmaTBARS
was measured using a colorimetric method as previously
described [11], and the values were expressed in nmol per mL
of malondialdehyde equivalents. TAC was assessed using an
Antioxidant Assay Kit (Cayman, USA). Nitric oxide synthesis
was assessed through nitrite measurement using the Griess
assay [12] expressed in 𝜇mol of nitrite.
2.6. Data Analysis. Descriptive analyses were performed
on absolute frequencies and percentages for categorical
variables. Numerical variables were described by the mean
and standard deviation. Statistical analyses were performed
using the SAS System for Windows 9.3 program and data
were analyzed using Chi-square, Fisher, Mann-Whitney, or
ANOVA for repeated measures tests. Multivariate logistic
regression analysis was performed to identify risk factors for
NMSC. The following covariates were used: age, race, smok-
ing, alcoholism, family history of cancer, 15-F2t-isoprostane,
TBARS, nitrite, and TAC, and two-sided 𝑝 values < 0.05
were considered statistically significant. When the sociode-
mographic characteristics differed between the groups, the
data were normalized and used in all regression analyses.
3. Results
3.1. Phase I. Sociodemographic characteristics, anthropo-
metric parameters, and levels of daily vitamin intake for
both groups (comparison and case groups) are detailed in
Table 2. Both groups contained more women than men.
Age, prolonged daily sunlight exposure, sunscreen use, and
previous family history of skin cancer were all significantly
higher in the case group.
Of the patients in the case group (𝑛 = 60), 85.0%had basal
cell carcinoma, while the remaining 15.0% had squamous
cell carcinoma. The face (80.0%) was the most common area
affected, followed by the trunk (8.3%), neck (6.7%), and other
areas (5.0%).
The case group had higher plasma concentrations of
all oxidative biomarkers assessed (Figure 2(a)). However,
only the increase in 15-F2t-isoprostane levels was statistically
significant (81.9 ± 36.4 pg/mL versus 46.2 ± 21.8 pg/mL, 𝑝 <
0.0001). Therefore, patients with a previous history of NMSC
4 BioMed Research International
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Lost to follow-up
Allocation
Analysis
Follow-up
Enrollment Assessed for eligibility (n = 302)
Analyzed (n = 34)
Lost to follow-up (n = 0)
Allocated to placebo (n = 34)
(noncompliance to supplementation) (n = 4)
Allocated to supplementation (n = 30)
Analyzed (n = 26)
Randomized (n = 64)
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the hospital being incorrect (n = 202)
(n = 2)
(ii) Declining to participate (n = 34)
Figure 1: Flow diagram of the passage of participants (Phase II).
were considered to have a relatively prooxidant cellular state
compared with healthy subjects.
Multivariate logistic regression analysis identified age
(𝑝 = 0.0050, odds ratio (OR) = 1.121, and 95% confidence
interval (CI) = 1.035–1.213) and the oxidative stress biomarker
15-F2t-isoprostane (𝑝 = 0.0099, OR = 1.044, and 95% CI =
1.010–1.078) as risk factors associated with NMSC. The risk
of NMSC increased by 12% each year and by 4% for each
additional 1 pg/mL increase in 15-F2t-isoprostane levels in the
plasma.
Table 2 shows that levels of daily vitamin C, vitamin E,
and zinc intake in the case group were lower than recom-
mended for both genders; therefore, vitamin C, vitamin E,
and zinc supplementation was clinically indicated (Phase II).
3.2. Phase II. The recruitment of participants to Phase II
is described in Figure 1. Sociodemographic characteristics,
anthropometric parameters, and levels of daily vitamin intake
for both groups (placebo and supplemented) are detailed in
Table 3. Placebo and supplementation subgroups had simi-
lar sociodemographic characteristics, except for alcoholism,
which was significantlymore prominent in the supplemented
subgroup.
A reduction of TAC (2.3mmol/L versus 2.1mmol/L), 15-
F2t-isoprostane (87.3 pg/mL versus 76.8 pg/mL), and TBARS
(90.0 nmol/L versus 60.0 nmol/L) levels after supplementa-
tion with antioxidants was observed, although these differ-
ences did not reach statistical significance compared with
placebo. Compared with baseline values, the group receiving
supplementation showed a reduction of both mean and
median plasma levels of 15-F2t-isoprostane, in addition to
a more homogeneous distribution of values, which was not
observed in the placebo group. The supplementation group
also showed a small increase of nitrite levels (10.9mmol/L
versus 15.0mmol/L), but this was not significantly different
from that of the placebo group (Figures 2(b) and 2(c)).
4. Discussion
Owing to the increasing incidence, morbidity, and mortality
of cancer worldwide, new diagnostic and screening methods
are needed for early detection. In recent years, knowledge
of cancer biomarkers has increased greatly and this presents
numerous opportunities to improve cancermanagement [13].
The present study demonstrated that plasma levels of 15-
F2t-isoprostane were significantly higher in patients with a
previous history of NMSC compared to healthy subjects.
Moreover, each additional 1 pg/mL of 15-F2t-isoprostane in
plasmawas associatedwith a 4% greater chance of developing
NMSC. Age was also found to be a risk factor for NMSC.
In addition, patients with history of NMSC had a cellular
prooxidant state compared to healthy subjects.
Oxidative stress has been implicated in various patholog-
ical conditions, including cancer. When evaluating a marker
for its importance in vivo, difficulties may arise because of
analytical problems relating to its specificity and sensitivity
[14]. Isoprostanes are certainly the most specific markers of
lipid peroxidation but are also the most difficult to measure
[14]. Several comprehensive reviews providing information
on the biochemistry of isoprostanes and their utilization as
markers of oxidative stress have been published in the last
decade [2, 14, 15].
BioMed Research International 5
Table 3: Comparison regarding sociodemographic characteristics from placebo and supplemented groups before supplementation.
Placebo (𝑛 = 34) Supplemented (𝑛 = 26) 𝑝 value
Sociodemographic characteristics
Age (years) (mean ± SD) 65.6 ± 13.2 59.0 ± 14.9 0.0860a
Sex (female), 𝑛 (%) 24 (70.6) 15 (57.7) 0.2994b
Smoking, 𝑛 (%) 4 (11.8) 4 (15.4) 0.7172c
Alcoholism, 𝑛 (%) 2 (5.9) 7 (26.9) 0.0323c
Use of sunscreen, 𝑛 (% ) 22 (64.7) 19 (73.1) 0.4987b
Mean daily sunlight exposure (mean ± SD) 199.4 ± 130.2 155.8 ± 112.5 0.2450a
Family history of cancer, 𝑛 (%) 24 (70.6) 18 (69.2) 0.9095b
Race, 𝑛 (%) 0.5072c
Caucasian 5 (14.7) 6 (23.1)
Non-Caucasian 29 (85.3) 20 (76.9)
Anthropometric parameters (mean ± SD)
BMI (kg/m2) 27.0 ± 4.1 25.8 ± 3.2 0.3440a
TSF (mm) 18.1 ± 7.4 17.5 ± 8.3 0.9100a
MUAC (cm) 30.0 ± 4.7 30.2 ± 4.2 0.6710a
MAMC (cm) 24.8 ± 4.0 24.1 ± 4.1 0.7670a
Daily intake levels (mean ± SD)
Vitamin A (𝜇g) 705.3 ± 778.6 428.2 ± 232.4 0.8817a
Vitamin C (mg) 55.7 ± 47.6 54.2 ± 46.5 0.7326a
Vitamin E (mg) 9.0 ± 4.0 9.9 ± 9.3 0.6157a
Cuprum (𝜇g) 950.0 ± 510.0 870.0 ± 280.0 0.0784a
Zinc (𝜇g) 7.1 ± 4.4 5.8 ± 2.4 0.1321a
Selenium (𝜇g) 79.8 ± 47.4 76.9 ± 21.5 0.1979a
𝑁= total of subjects/patients, SD = standard deviation, BMI = bodymass index, TSF = triceps skinfold,MUAC=mid-upper-arm circumference, andMAMC=
mid-arm muscle circumference. Statistical analysis: aMann-Whitney test; bChi-square test; cFisher’s exact test.
Isoprostanes are prostaglandin isomers produced by per-
oxidation of polyunsaturated fatty acids from the cellular
membrane. The most frequent isomer released into the
circulation is 15-F2t-isoprostane, which has been identified as
a promising key biomarker to investigate the role of oxidative
injury [16] in several diseases, including cancer. Barocas et al.
[17] reported that increased levels of isoprostanes are present
in the urine of patients with prostate cancer. Moreover,
Rossner Jr. et al. [18] presented evidence that increased
levels of isoprostanes may be correlated with an increased
risk of breast cancer. Belli et al. [19] showed that 15-F2t-
isoprostane levels were increased in basal cell carcinoma
and in healthy skin previously exposed to UVA irradiation.
Increased levels of isoprostanes have also been reported in
several acute and chronic diseases including cardiovascular
and neurodegenerative pathologies and cancer, as well as
during the normal aging process [16, 20].
As oxidative stress is widely believed to cause or aggravate
several human pathologies as described above, it is possible
that antioxidants could counteract the harmful effects caused
by a prooxidant profile and prevent or treat oxidative stress-
related diseases. Herein, it was observed that daily intake
levels of vitamins C and E in the case group were lower than
those recommended (DRI guidelines). After supplementa-
tion, there was no significant reduction in levels of oxidative
stress biomarkers. However, there was a small reduction in
plasma levels of all oxidative biomarkers evaluated, especially
15-F2t-isoprostane. Both mean and median plasma levels of
15-F2t-isoprostane were reduced after supplementation, and
there was a more homogeneous distribution of values in this
group. Additional studies on the modulation of isoprostanes
by antioxidant nutrients have recently been published. For
example, Reilly et al. [21] reported that vitamin C admin-
istered to heavy smokers for 5 days at 2 g/day significantly
reduced isoprostane excretion in their urine. Moreover, Davi
et al. [22, 23] described a significant reduction in urinary
isoprostane excretion in patients with diabetes mellitus and
hypercholesterolemia after supplemental therapy with vita-
min E.
Our study did not show a significant reduction in the
levels of 15-F2t-isoprostane after supplementation with vita-
min C, vitamin E, and zinc for 60 days. However a study
conducted by Dietrich et al. [24], in which patients were
supplemented for 60 days with vitamin C at 500mg/day and
vitamin E at 300mg/day, showed a statistically significant
reduction in the plasma levels of 15-F2t-isoprostane. These
doses were similar to those used by our study. In a study
using doses of vitamin C lower than 500mg/day and doses
of vitamin E lower than 300mg/day, a longer period of sup-
plementation did not lead to showing a significant reduction
in plasma levels of biomarkers of oxidative stress [25]. In a
study byMurer et al. [26], there was a significant reduction of
over 30% (𝑝 = 0.014) of 15-F2t-isoprostane levels in the urine
of obese children after supplementation with 500mg/day of
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Figure 2: Mean values of oxidative stress biomarkers from each group present in the study: (a) Phase I/comparison and case groups, (b)
Phase II/case group (placebo): basal and after supplementation, and (c) Phase II/case group (supplemented): basal and after supplementation.
ANOVA for repeated measures statistical test; astatistically significant difference in relation to comparison group.
vitamin C, 400 IU/day of vitamin E, and 50mg/day of sele-
nium for 119 days.
In a recent study by Roberts II et al. [27], the influ-
ence of the dose of vitamin E on the reduction of 15-F2t-
isoprostane was examined in patients with coronary artery
disease. The study was initially carried out with patients
supplemented with 3200 IU/day vitamin E for 20 weeks and
then participants were supplemented with a dose of 0, 100,
200, 400, 800, 1600, or 3200 IU/day vitamin E for 16 weeks.
Maximum suppression of plasma levels of 15-F2t-isoprostane
did not occur until the 16th week of supplementation and
the percentage reduction in plasma concentrations of 15-F2t-
isoprostane only reached significance at doses of 1600 IU/day
and 3200 IU/day. These data reveal the dose-dependent
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effects of antioxidant supplementation for the reduction of
biomarkers of oxidative stress and indicate that the dose
and time of supplementation should be chosen carefully to
achieve the desired result.
This study has some limitations: a relatively small sample
size; a short period of antioxidant supplementation; a lack
of information about cancer types (primarily skin cancer)
in families; a lack of past information about smoking, alco-
hol habits, use of sunscreen, and sunlight exposure; and a
lack of a robust classification for smoking, alcohol habits, and
use of sunscreen. In addition, the results of the immunoas-
says could be confounded by the structural similarities
between isoprostanes and some prostaglandins; therefore,
15-F2t-isoprostane should preferably be quantified by mass
spectrometry.
5. Conclusion
The present study demonstrated that patients with a history
of NMSC had a statistically significant increase in plasma
levels of 15-F2t-isoprostane.This suggests that oxidative stress
may play an important role in the pathogenesis of skin
cancers. Moreover, to the authors’ knowledge, this is the
first demonstration that increased plasma levels of 15-F2t-
isoprostane are a risk factor for NMSC. The supplementary
antioxidant therapy did not cause significant reduction in
levels of oxidative stress biomarkers, so there is need for fur-
ther evaluation of these supplements as long-term adjunctive
therapy.
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